Study limitation: The trial is exploratory and underpowered for the primary hepatotoxicity outcome; the wide CI (OR 0.01–5.75) means a clinically important difference cannot be ruled out | ReachRx
Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Study limitation reported by the research below: “The trial is exploratory and underpowered for the primary hepatotoxicity outcome; the wide CI (OR 0.01–5.75) means a clinically important difference cannot be ruled out.”
